Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19Funding and Resources No funding was received for this study by any entity in the public or private sector.
The understanding of coronavirus disease 2019 (COVID-19) is evolving periodically. There is also a marked increase in COVID-19 patients’ demand for the provision of COVID-19 convalescent plasma (CCP) therapy. With the review of the literature, the stage of speculation is quickly moving towards conformity, with the interim guidelines given by the Food and Drug Administration (FDA) in the United States, United Kingdom’s blood transfusion services, Saudi’s FDA, and the Indian Council for Medical Research, in addition to the European health authorities. It is prudent to address the ethical concerns that merit consideration while harvesting and utilizing CCP as a therapeutic tool in local hospital setting.
Keywordsasymptomatic carriers - ethical concerns - blood donation - blood safety - blood transfusion services - convalescent plasma - COVID-19 - regular screening
24. April 2021 (online)
© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Sahu KK, Mishra AK, Raturi M, Lal A. Current perspectives of convalescent plasma therapy in COVID-19. Acta Biomed 2020; 91 (04) e2020175
- 2 World Health Organization rolling updates on coronavirus disease (COVID-19);2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed March 17, 2020
- 3 Raturi M, Kusum A. The blood supply management amid the COVID-19 outbreak. Transfus Clin Biol 2020; 27 (03) 147-151
- 4 Raturi M. A quick “can I donate blood” self-assessment tool amid the COVID-19 outbreak. Transfus Clin Biol 2020; 27 (03) 169-170
- 5 American Association of Blood Banks (AABB)’s Coronavirus Resources;2020. Available at: http://www.aabb.org/advocacy/regulatorygovernment/Documents/Impact-of-2019-Novel-Coronavirus-on-Blood-Donation.pdf. Accessed March 18, 2020
- 6 American Society of Hematology. Clinical news: online exclusives. Available at: https://www.ashclinicalnews.org/online-exclusives/fda-allows-blood-plasma-treatment-coronavirus-case-case-basis/. Accessed April 07, 2020
- 7 Raturi M, Kusum A. The active role of a blood center in outpacing the transfusion transmission of COVID-19. Transfus Clin Biol 2020; 27 (02) 96-97
- 8 Raturi M, Shastry S, Murugesan M, Baliga PB, Chakravarthy K. Effect of plasma component transfusion on conventional coagulation screening tests. Asian J Transfus Sci 2018; 12 (01) 57-61
- 9 Directorate General Health Services, Government of India. Clinical trial of convalescent plasma in COVID-19 patients. [17.04.2020] Available at: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTg2Mw==. Accessed May 29, 2020
- 10 Park WH. Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. JAMA 1932; 99(13): 1050-1053
- 11 Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38 suppl. 4 e66-e73
- 12 Rambar AC. Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child 1946; 71: 1-13
- 13 Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health Nations Health 1935; 25 (05) 595-598
- 14 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145 (08) 599-609
- 15 Beigel JH, Aga E, Elie-Turenne M-C. et al. IRC005 Study Team. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2019; 7 (11) 941-950
- 16 van Griensven J, Edwards T, de Lamballerie X. et al. Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med 2016; 374 (01) 33-42
- 17 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
- 18 US Food and Drug Administration. Recommendations for Investigational COVID-19 convalescent plasma. FDA. 2020. Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed June 24, 2020
- 19 Netherlands: International Society of Blood Transfusion. The ISBT code of ethics. Available at: http://www.isbtweb.org/fileadmin/user_upload/_About_ISBT/ISBT_Code_of_Ethics_English.pdf. Accessed February 4, 2021
- 20 Albalawi M, Zaidi SZA, AlShehry N. et al. Safety and efficacy of convalescent plasma to treat severe COVID-19: protocol for the Saudi collaborative multicenter phase II study. JMIR Res Protoc 2020; 9 (10) e23543
- 21 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117 (17) 9490-9496
- 22 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
- 23 ISBT/IHN. ISBT/IHN 2014 definitions for complications related to blood donation. Standard for Surveillance of Complications Related to Blood Donation. Available at: https://www.isbtweb.org/fileadmin/user_upload/Donor_Standard_Definitions_Final_2014.pdf. Accessed June 23, 2020
- 24 Pandey S, Vyas GN.. Adverse effects of plasma transfusion. TRANSFUSION 2012 52 (Suppl. 01) 65S-79S